Evidence map›Paper›PMID 42599973›Full record

ArticlePLoS pathogens2026

Engineered Lactobacillus paracasei 3×pBD1/ΔHLJ-27 as a novel antibiotic alternative for livestock: Dual efficacy in growth promotion and protection against Salmonella infection via integrated host-microbiota-immune regulation.

Yijie Yang, Ying Chen, Haiyuan Zhao, Zhaojun Wang, Meijun Yu, Xijiao Shao, Yin Zhu, Ping Han, Tianyu Han, Wen Cui and 5 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yijie YangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Ying ChenCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Haiyuan ZhaoCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Zhaojun WangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Meijun YuCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Xijiao ShaoCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Yin ZhuCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Ping HanCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Tianyu HanCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Wen CuiCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Yanping JiangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Lijie TangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Yijing LiCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Jiaxuan LiCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.
Xiaona WangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin, China.ORCID 0000-0002-5724-3025

Funding

Heilongjiang Postdoctoral Foundation (General Program, First Class)National Natural Science Foundation of ChinaTechnology Support Program of Fourteenth Five Year Plan
6 · The paper itself

Abstract

To address the antimicrobial resistance (AMR) crisis driven by livestock agriculture, effective antibiotic alternatives are urgently needed. However, current probiotic and antimicrobial peptide strategies are critically hindered by limited efficacy, poor stability, and a lack of systemic protection. This study employed recombinant Lactobacillus paracasei 3 × pBD1/ΔHLJ-27, which can secrete and express multicopy porcine β-defensin-1 (pBD1), a cationic antimicrobial peptide with broad-spectrum activity. The study demonstrate that this engineered strain confers systemic protection against Salmonella Typhimurium (S. Typhimurium) infection by coordinately enhancing intestinal barrier integrity and modulating host immune responses. Specifically, 3 × pBD1/ΔHLJ-27 improved intestinal morphology and upregulated tight junction proteins, while promoting balanced immune activation characterized by increased CD4 ⁺ T cells and elevated SIgA and IgG levels. In infection models, the strain significantly reduced mortality, limited bacterial dissemination, and alleviated intestinal pathology. Mechanistically, these protective effects are associated with suppression of excessive inflammatory responses and reprogramming of host-microbiota interactions, as evidenced by reduced pro-inflammatory signaling and enrichment of beneficial microbial taxa. Collectively, these findings identify 3 × pBD1/ΔHLJ-27 as a multifunctional engineered probiotic that integrates antimicrobial activity with immune regulation, offering a promising and scalable alternative to antibiotics in animal production.

Indexed as

beta-DefensinsGastrointestinal MicrobiomeLacticaseibacillus paracaseiProbioticsSalmonella Infections, AnimalSalmonella typhimuriumAnimalsAnti-Bacterial AgentsIntestinal Barrier FunctionMiceSwineAnti-Bacterial Agentsbeta-Defensins

Identifiers

PMID42599973
PMCPMC13475985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.